骨质疏松性骨折1年和2年发病率:多队列观察研究
该多国队列研究利用英国、西班牙和丹麦常规收集的真实世界数据,估计高风险骨折患者1至2年内的骨折风险。新诊断骨质疏松的老年人和接受双膦酸盐治疗期间发生骨折的患者面临较高的即时骨折风险。发生骨质疏松性骨折或治疗期间骨折的个体再骨折发生率高于有或无治疗的骨质疏松患者。
要点
- 新诊断骨质疏松的老年人和双膦酸盐治疗期间骨折者即时骨折风险高。
- 骨折后个体再骨折发生率高于仅骨质疏松患者。
- 各国骨折发生率差异明显,丹麦多数结局发生率最高。
核心结论
- 发生骨质疏松性骨折或双膦酸盐治疗期间骨折的个体再骨折发生率高于有或无治疗的骨质疏松患者。
研究设计与样本
- 多队列观察研究,使用英国CPRD(1995-2017)、西班牙SIDIAP(2006-2016)和丹麦DHR(1995-2016)数据库,纳入≥50岁个体,分为新诊断骨质疏松、 incident骨质疏松性骨折、 incident口服双膦酸盐使用和治疗期间骨折四组。
主要发现
- 新诊断骨质疏松组1年髋部骨折发生率西班牙最低为4.7/1000人,丹麦最高为74.2/1000人。
- incident骨质疏松性骨折组1年主要骨质疏松性骨折发生率丹麦最高为47.2/1000人,英国最低为20.7/1000人。
- 口服双膦酸盐使用组1年髋部骨折发生率西班牙最低为5.0/1000人,丹麦最高为20.3/1000人。
- 治疗期间骨折组1年临床脊柱骨折发生率西班牙最高为12.0/1000人,髋部骨折发生率西班牙最低为7.6/1000人、丹麦最高为33.6/1000人。
临床怎么用
- 对新诊断骨质疏松和双膦酸盐治疗期间骨折的患者应警惕高即时骨折风险,考虑强化评估与干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We estimated and characterized the imminent fracture risk (1-2 years) of high-risk fracture patients through a multinational (UK, Spain, Denmark) cohort study. Older individuals with newly diagnosed osteoporosis and individuals who had a fracture while on treatment with a bisphosphonate were at a high risk of imminent fracture. PURPOSE: To characterize and estimate 1- to 2-year fracture risk in high-risk fracture patients. METHODS: Multi-cohort study in (database/study period) UK (CPRD/1995-2017), Spain (SIDIAP/2006-2016) and Denmark (DHR/1995-2016) including individuals ≥ 50 years old in NDO (newly diagnosed osteoporosis), OFx (incident osteoporotic fracture), BP (incident oral bisphosphonates use) or FWOT (fracture while on treatment with bisphosphonates). Outcomes (ICD-10/READ): hip, clinical spine, non-hip, non-spine and hip/humerus/distal forearm fracture. FOLLOW-UP: from cohort entry until death, migration/transfer or end of the study. STATISTICS: baseline characteristics and incidence rate (IR per 1000 persons). RESULTS (1-YEAR IR): NDO included 69,899 (UK), 37,901 (Spain) and 158,191 (Denmark) individuals. Spanish-IR was lowest for hip (4.7), clinical spine (2.5) and major osteoporotic fracture (MOF) (17.3) and highest in Denmark (74.2, 26.0 and 120.1, respectively). OFx included 83,514 (UK), 51,044 (Spain) and 509,551 (Denmark) individuals. IR in Denmark was highest for hip (24.1) and MOF (47.2), in Spain was highest for the clinical spine (9.4) and lowest for hip (9.5) and in the UK was lowest for the clinical spine (2.8) and MOF (20.7). BP included 148,507 (UK), 52,037 (Spain) and 204,010 (Denmark) individuals. Spanish-IR was lowest for hip (5.0) and MOF (21.1) and highest in Denmark (20.3 and 48.6, respectively). FWOT included 28,930 (UK), 1,865 (Spain) and 31,882 (Denmark) individuals. Clinical spine-IR was highest for Spain (12.0). Hip-IR was lowest for Spain (7.6) and highest for Denmark (33.6). Comparing young subjects, those who have FWOT started with an increased fracture rate. CONCLUSION: OFx and FWOT individuals experience higher re-fracture incidence rates than those with osteoporosis with or without treatment.
引用
- Khalid S, Reyes C, Ernst M, et al. One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. Osteoporos Int. 2021. PMID: 34392386. doi:10.1007/s00198-021-06077-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。